

- 隆. HLAクラスII不適合骨髄移植患者より樹立した不一致クラスII拘束性アロCD8+CTLクローンの解析: 第1回造血器腫瘍免疫療法研究会学術集会、大阪市、2009年8月
- 8) 葛島清隆、岡村文子、鳥飼宏基、赤塚美樹. 新規腫瘍抗原探索を目的とした人工抗原提示細胞システムの検討: 第1回造血器腫瘍免疫療法研究会学術集会、大阪市、2009年8月
 - 9) 岡村(出町)文子、森島聡子、渡邊友紀子、鳥飼宏基、赤塚美樹、葛島清隆. 人工抗原提示細胞を使った新規腫瘍抗原の同定: 第68回日本癌学会学術総会、横浜市、2009年10月
 - 10) 鳥飼宏基、渡邊友紀子、岡村文子、高橋利忠、森島泰雄、葛島清隆、赤塚美樹. HLAクラスII不適合骨髄移植患者より樹立した不一致クラスII拘束性アロCD8+CTLクローンの解析: 第68回日本癌学会学術総会、横浜市、2009年10月
 - 11) 藤原弘、越智俊元、永井功造、白方俊章、峰野純一、葛島清隆、安川正貴. Aurora-A kinase特異的T細胞受容体(TCR)遺伝子を用いた免疫遺伝子療法の検討: 第68回日本癌学会学術総会、横浜市、2009年10月
 - 12) 越智俊元、藤原弘、白方俊章、葛島清隆、峰野純一、小澤秀俊、石川文彦、安川正貴. 造血幹細胞へのWT1特異的T細胞レセプター遺伝子導入による新たな免疫遺伝子療法の開発: 第68回日本癌学会学術総会、横浜市、2009年10月
 - 13) 鳥飼宏基、柳澤真弓、今橋伸彦、渡邊友紀子、岡村文子、高橋利忠、宮村耕一、森島泰雄、小寺良尚、葛島清隆、赤塚美樹. HLAクラスII不適合骨髄移植患者より樹立した不一致クラスII拘束性アロCD8+CTLクローンの解析: 第71回日本血液学会学術集会、京都市、2009年10月
 - 14) 高橋義行、ブストス イツツエル、村松秀城、西尾信博、永田俊人、濱 麻人、加藤元博、小川 誠司、赤塚美樹、小島 勢二. ハプロ一致幹細胞移植後の白血病再発メカニズム: 6番染色体短腕欠失による免疫監視機構からの逃避. 第71回日本血液学会総会、京都 2009年10月.
 - 15) 鳥飼宏基、亀井美智、南谷泰仁、川瀬孝和、森島泰雄、高橋利忠、葛島清隆、小川誠司、赤塚美樹. Public Resource を用いたゲノムワイド解析による新規マイナー抗原同定法の開発: 第12回基盤的癌免疫研究会総会、さいたま市、2008年7月
 - 16) 渡邊友紀子、岡村文子、森島聡子、鳥飼宏基、赤塚美樹、葛島清隆. Induction of EBNA1-specific CD4⁺T lymphocytes by CD40-activated B cells electroporated with mRNA encoding EBNA1: 第67回日本癌学会学術総会、名古屋、2008年10月
 - 17) 赤塚美樹、森島泰雄. 骨髄移植症例に誘導されるGVL効果の解析. 第67回日本癌学会総会シンポジウム、名古屋、2008年10月
 - 18) Ogawa S, Matsubara A, Kashiwase K, Akatsuka Y, et al. Genome-wide association studies of genetic incompatibility that is relevant to the development of GvHD in unrelated bone marrow transplantation. 第50回米国血液学会総会、サンフランシスコ 2008年12月
 - 19) Nannya Y, Kamei M, Torikai H, Kawase T, Taura K, Inamoto Y, Takahashi Ta, Yazaki M, Morishima S, Miyamura K, Ito T, Kodera Y, Morishima Y, Takahashi T, Kuzushima K, Ogawa S, and Akatsuka Y. HapMap scanning of novel human minor histocompatibility antigens: 第50回米国血液学会総会、サンフランシスコ、2008年12月
 - 20) 葛島清隆. 人工抗原提示細胞を使った新規腫瘍抗原同定の試み: 第19回群馬

- Clinical Oncology Research勉強会、前橋市、2008年12月
- 21) 赤塚美樹. Minor Antigen 反応性CTLの移植医療への関与. 第31回日本造血細胞移植学会総会、シンポジウム、札幌市、2009年2月
 - 22) 岡村文子、渡邊友紀子、長尾 隆志、森島聡子、赤塚美樹、高橋利忠、葛島清隆. EBウイルス核抗原EBNA1特異的CD4⁺T細胞の誘導と機能解析：第11回基盤的癌免疫研究会総会、東京、2007年7月
 - 23) 川瀬孝和、赤塚美樹、鳥飼宏基ら. HMSD遺伝子に由来する新規マイナー抗原ACC-6の同定と白血病幹細胞におけるACC-6の発現. 第11回基盤的がん免疫研究会総会、東京 2007年7月
 - 24) 夏目敦至、辻村邦夫、葛島清隆、近藤豊、関戸好孝、島戸真司、伊藤元一、若林俊彦、吉田純. Epigenetic target for cancer-testis antigen-based tumor immunotherapy: 第66回日本癌学会学術総会、横浜、2007年10月
 - 25) 岡村文子、渡邊友紀子、森島聡子、赤塚美樹、森島泰雄、高橋利忠、葛島清隆. EBウイルス核抗原EBNA1特異的CD4⁺T細胞の機能解析：第66回日本癌学会学術総会、横浜、2007年10月
 - 26) 鳥飼宏基、赤塚美樹、谷田部恭ら. BCL2A1にコードされる血液細胞特異的マイナー組織適合抗原のメラノーマにおける異所性発現. 第66回日本癌学会総会、横浜 2007年10月
 - 27) 川瀬孝和 南谷泰仁 赤塚美樹ら. 遺伝子連鎖解析によるHLA-A*2402拘束性の新規マイナー組織適合性抗原の同定. 第69回日本血液学会総会・第49回日本臨床血液学会総会、横浜 2007年10月
 - 28) 赤塚美樹. GVHDを増強せずにGVL効果をも高める治療法の可能性（シンポジウム）. 第69回日本血液学会総会・第49回日本臨床血液学会総会、横浜 2007年10月
 - 29) 赤塚美樹. 造血器腫瘍に対する細胞免疫療法の後（教育講演）. 第69回日本血液学会総会・第49回日本臨床血液学会総会、横浜 2007年10月
 - 30) 赤塚美樹. マイナー組織適合抗原を標的とした免疫療法. 第55回日本輸血学会総会（教育講演）、名古屋 2007年5月
 - 31) Kawase T, Morishima Y. et al. Identification of HLA Allele Mismatch Combinations and Amino Acid Substitution Positions Associated with GVL Effect after Unrelated HSCT. 49th annual meeting of American Society of Hematology, Dec. 2007. Atlanta, USA
 - 32) 亀井美智、南谷泰仁、赤塚美樹ら. 新規遺伝子連鎖解析法によるHLA-B*4002拘束性のマイナー組織適合性抗原の同定. 第30回日本造血細胞移植学会総会、シンポジウム、大阪 2008年2月
- H. 知的財産権の出願・登録状況
特に無し

II. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Villalobos IB, Takahashi Y, <u>Akatsuka Y</u> , Muramatsu H, Nishio N, Hama A, Yagasaki H, Saji H, Kato M, Ogawa S, Kojima S.	Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation.	<i>Blood</i>	115	3158-61	2010
Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y, Takahashi T, Yazaki M, Morishima S, Tsujimura K, Miyamura K, Ito T, Togari H, Riddell SR, Koder Y, <u>Morishima Y</u> , Takahashi T, <u>Kuzushima K</u> , Ogawa S, <u>Akatsuka Y</u> .	HapMap scanning of novel human minor histocompatibility antigens.	<i>Blood</i>	113	5041-5048	2009
Yasukawa M, Fujiwara H, Ochi T, Suemori K, Narumi H, Azuma T, <u>Kuzushima K</u> .	Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.	<i>Am J Hematol.</i>	84	314-315	2009
Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, <u>Kuzushima K</u> , Nakayama E.	Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.	<i>Cancer Immun.</i>	9	8-17	2009
Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Muto S, Tamura A, Iio M, <u>Akatsuka Y</u> , Hayashi Y, Mori H, Igarashi T, Kurokawa M, Chiba S, Mori S, Ishikawa Y, Okamoto K, Tobinai K, Nakagama H, Nakahata T, Yoshino T, Kobayashi Y, Ogawa S.	Frequent inactivation of A20 in B-cell lymphomas.	<i>Nature</i>	459	712-716	2009
Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, <u>Kuzushima K</u> , Yasukawa.	M.Aurora-A kinase: A novel target of cellular immunotherapy for leukemia.	<i>Blood</i>	113(1)	66-74	2009
Ogawa S, Matsubara A, Onizuka M, Kashiwase K, Sanada M, Kato M, Nannya Y, Akatsuka Y, Satake M, Takita J, Chiba S, Saji H, Maruya E, Inoko H, <u>Morishima Y</u> , Koder Y, Takehiko S; Japan Marrow Donation Program (JM DP).	Exploration of the genetic basis of GVHD by genetic association studies. Biol	<i>Biol. Blood Marrow Transplant.</i>	15(1 Suppl)	39-41	2009

Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, <u>Morishima Y</u> , Kodera Y, Kato S.	Disease-specific analyses of unrelated cord blood transplant compared with unrelated bone marrow transplant in adult patients with acute leukemia.	<i>Blood</i>	113(8)	1631-8	2009
Ishizawa K, Ogura M, Hamaguchi M, Hotta T, Ohnishi K, Sasaki T, Sakamaki H, Yokoyama H, Harigae H, <u>Morishima Y</u> .	Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study.	<i>Cancer Sci.</i>	100(2)	357-362	2009
Kim SW, Mori SI, Tanosaki R, Fukuda T, Kami M, Sakamaki H, Yamashita T, Kodera Y, Terakura S, Taniguchi S, Miyakoshi S, Usui N, Yano S, Kawano Y, Nagatoshi Y, Harada M, <u>Morishima Y</u> , Okamoto S, Saito AM, Ohashi Y, Ueda R, Takaue Y.	Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.	<i>Bone Marrow Transplant.</i>	43(8)	611-7	2009
Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S, Kato S, Sasazuki T, Kodera Y, <u>Morishima Y</u> .	HLA mismatch combinations associated with decreased risk of relapse: Implications for molecular mechanism.	<i>Blood</i>	113(12)	2851-8	2009
Lu X, Kondo Y, Takamatsu H, Ohata K, Yamazaki H, Takami A, <u>Akatsuka Y</u> , Nakao S.	CD16 ⁺ CD56- NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft-versus-leukemia effect.	<i>Eur. J. Haematol.</i>	81	18-25	2008
Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, <u>Kuzushima K</u> , Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J.	The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.	<i>Int. J. Cancer.</i>	122(11)	2542-53	2008
Demachi-Okamura A, Ito Y, <u>Akatsuka Y</u> , Tsujimura K, <u>Morishima Y</u> , Takahashi T, <u>Kuzushima K</u> .	Epstein-Barr virus nuclear antigen 1-specific CD4 ⁺ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.	<i>Cancer Sci.</i>	99(8)	1633-42	2008
Akamatsu T, Watanabe N, Kido M, Saga K, Tanaka J, <u>Kuzushima K</u> , Nishio A, Chiba T.	Human TSLP directly enhances expansion of CD8 ⁺ T cells.	<i>Clin. Exp. Immunol.</i>	154(1)	98-106	2008
Torikai H, <u>Akatsuka Y</u> , Yatabe Y, <u>Morishima Y</u> , Kodera Y, <u>Kuzushima K</u> , Takahashi T.	Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.	<i>Int. J. Hematol.</i>	87	467-473	2008
Watanabe K, Suzuki S, Kamei M, Toji S, Kawase T, Takahashi T, <u>Kuzushima K</u> , <u>Akatsuka Y</u> .	CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy.	<i>Int. J. Hematol.</i>	88	311-320	2008

Shimato S, Natsume A, Tsujimura K, Nakahara N, Wakabayashi T, Ishii J, Ito M, Akatsuka Y, <u>Kuzushima K</u> , Yoshida J.	Identification of an HLA-A24-restricted T-cell epitope derived from a glioma-associated antigen, interleukin 13 receptor $\alpha 2$ chain.	<i>J. Neurosurg.</i>	109(1)	117-22	2008
Kawase T, Nannya Y, Torikai H, Yamamoto G, Onizuka M, Morishima S, Tsujimura K, Miyamura K, Koder Y, <u>Morishima Y</u> , Takahashi T, <u>Kuzushima K</u> , Ogawa S, <u>Akatsuka Y</u> .	Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA.	<i>Blood</i>	111(6)	3286-94	2008
Okii Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, <u>Morishima Y</u> .	Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.	<i>Eur. J. Haematol.</i>	81(6)	448-53	2008
Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, Yoshino T, Suzumiya J, Murase T, Miura I, Ohshima K, Nishikori M, Tamaru J, Taniwaki M, Hirano M, <u>Morishima Y</u> , Ueda R, Shiku H, Nakamura S.	De novo CD5 ⁺ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.	<i>Haematologica</i>	93(8)	1195-202	2008
Rosinski KV, Fujii N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, Gibbs JS, Radich JP, <u>Akatsuka Y</u> , Van den Eynde BJ, Riddell SR, Warren EH.	DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.	<i>Blood</i>	111(9)	4817-26	2008
Okii Y, Kato H, Matsuo K, Kuwatsuka Y, Taji H, Yamamoto K, Kagami Y, <u>Morishima Y</u> .	Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy.	<i>Leuk. Lymphoma</i>	49(7)	1345-51	2008
Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, Ogawa A, Takanashi M, Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Koder Y, <u>Morishima Y</u> for the Japan Marrow Donor Program.	Donor killer immunoglobulin-like receptor (KIR) genotype and anti-thymocyte globulin pre-administration are critical factors in outcome of HLA-C-KIR ligand mismatched T cell-replete unrelated bone marrow transplantation.	<i>Biology Blood Marrow Transplant.</i>	14(1)	75-87	2008
Ikehara Y, Shiuchi N, Kabata-Ikehara S, Nakanishi H, Yokoyama N, Takagi H, Nagata T, Koide Y, <u>Kuzushima K</u> , Takahashi T, Tsujimura K, Kojima N.	Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.	<i>Cancer Letters</i>	260(1-2)	137-145	2008

Kawase T, <u>Akatsuka Y</u> , Torikai H, Morishima S, Oka A, Tsujimura A, Miyazaki M, Tsujimura K, Miyamura K, Ogawa S, Inoko H, <u>Morishima Y</u> , Kodera Y, <u>Kuzushima K</u> , Takahashi T.	Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen.	<i>Blood</i>	110(3)	1055-1063	2007
<u>Akatsuka Y</u> , <u>Morishima Y</u> , <u>Kuzushima K</u> , Kodera Y, Takahashi T.	Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.	<i>Cancer Sci.</i>	98(8)	1139-1146	2007
Torikai H, <u>Akatsuka Y</u> , Miyauchi H, Terakura S, Onizuka M, Tsujimura K, Miyamura K, <u>Morishima Y</u> , Kodera Y, <u>Kuzushima K</u> , Takahashi T.	The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.	<i>Bone Marrow Transplant.</i>	40(2)	165-174	2007
Ito Y, Demachi-Okamura, A, Ohta R, <u>Akatsuka Y</u> , Nishida K, Tsujimura K, <u>Morishima Y</u> , Takahashi T, <u>Kuzushima K</u> .	Full-length EBNA1-mRNA-transduced dendritic cells stimulate CTLs recognizing a novel HLA-Cw*0303 and Cw*0304-restricted epitope on EBNA1-expressing cells.	<i>J. Gen. Virol.</i>	88(Pt 3)	770-80	2007
Kawase T, <u>Morishima Y</u> , Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y, Sasazuki T; Japan Marrow Donor Program.	High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism.	<i>Blood</i>	110(7)	2235-41	2007
Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, <u>Morishima Y</u> , Takeuchi K, Izumo T, Mori S, Ohshima K, Suzumiya J, Nakamura N, Abe M, Ichimura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya Y, Kinoshita T, Nakamura S.	Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.	<i>Clin Cancer Res.</i>	13(17)	5124-32	2007
<u>Morishima Y</u> , Kawase T, Malkki M, Petersdorf EW; International Histocompatibility Working Group in Hematopoietic Cell Transplantation Component.	Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell transplantation from unrelated donors.	<i>Tissue Antigens</i>	69 (Suppl 1)	31-5	2007
Setterholm M, <u>Morishima Y</u> , Pepperall J, Schmidt A.	Strategies for typing new volunteer donors.	<i>Tissue Antigens</i>	69 (Suppl 1)	6-7	2007
Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, <u>Morishima Y</u> , Kodera Y; Japan Marrow Donor Program.	Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.	<i>Br J Haematol.</i>	137(2)	142-51	2007

Yamada K, Takahashi M, Ogura M, Kagami Y, Taji H, Kamiya Y, Sugiura H, <u>Morishima Y</u> .	High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas.	<i>Bone Marrow Transplant.</i>	39(8)	471-6	2007
Mizuta S, Kohno A, Morishita Y, Atsuta Y, Sao H, Miyamura K, Sakamaki H, Ueda R, <u>Morishima Y</u> .	Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission.	<i>Int J Hematol.</i>	85(2)	140-5	2007
<u>Morishima Y</u> , Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H, Yamamoto K, Maruya E, <u>Akatsuka Y</u> , Onizuka M, Sakamaki H, Sao H, Ogawa S, Kato S, Juji T, Sasazuki T, Kodera Y; Japan Marrow Donor Program.	Effects of HLA Allele and Killer Immunoglobulin-Like Receptor Ligand Matching on Clinical Outcome in Leukemia Patients Undergoing Transplantation With T-cell-Replete Marrow From an Unrelated Donor.	<i>Biol Blood Marrow Transplant.</i>	13(3)	315-28	2007
Kikuchi T, Naruse TK, Onizuka M, Li S, Kimura T, Oka A, <u>Morishima Y</u> , Kulski JK, Ichimiya S, Sato N, Inoko H.	Mapping of susceptibility and protective loci for acute GVHD in unrelated HLA-matched bone marrow transplantation donors and recipients using 155 microsatellite markers on chromosome 22.	<i>Immunogenetics</i>	59(2)	99-108	2007
Inamoto Y, Nishida T, Suzuki R, Miyamura K, Sao H, Iida H, Naoe T, Maruyama F, Hirabayashi N, Hamaguchi M, Iseki T, Kami M, Yano K, Takeyama H, Morishita Y, <u>Morishima Y</u> , Kodera Y.	Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.	<i>Bone Marrow Transplant.</i>	39(1)	25-30	2007
Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, Shibuya T, Utsunomiya A, Kawase T, Kato S, <u>Morishima Y</u> , Kodera Y, Harada M; Japan Marrow Donor Program.	Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.	<i>Biol Blood Marrow Transplant.</i>	13(1)	90-9	2007

III. 研究成果の刊行物・別刷

Brief report

Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation

Itzel Bustos Villalobos,¹ Yoshiyuki Takahashi,¹ Yoshiki Akatsuka,^{2,3} Hideki Muramatsu,¹ Nobuhiro Nishio,¹ Asahito Hama,¹ Hiroshi Yagasaki,¹ Hiroh Saji,⁴ Motohiro Kato,⁵ Seishi Ogawa,⁶ and Seiji Kojima¹

¹Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya; ²Division of Immunology, Aichi Cancer Center Research Institute, Nagoya; ³Department of Hematology and Oncology, Fujita Healthy University, Aichi; ⁴Human Leukocyte Antigen Laboratory, Nonprofit Organization, Kyoto; ⁵Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo; and ⁶21st Century Center of Excellence Program, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

We investigated human leukocyte antigen (HLA) expression on leukemic cells derived from patients at diagnosis and relapse after hematopoietic stem cell transplantation (HSCT) using flow cytometry with locus-specific antibodies. Two of 3 patients who relapsed after HLA-haploidentical HSCT demonstrated loss of HLA alleles in leukemic cells at re-

lapse; on the other hand, no loss of HLA alleles was seen in 6 patients who relapsed after HLA-identical HSCT. Single-nucleotide polymorphism array analyses of sorted leukemic cells further revealed the copy number-neutral loss of heterozygosity, namely, acquired uniparental disomy on the short arm of chromosome 6, resulting in the total loss of the mis-

matched HLA haplotype. These results suggest that the escape from immunosurveillance by the loss of mismatched HLA alleles may be a crucial mechanism of relapse after HLA-haploidentical HSCT. Accordingly, the status of mismatched HLA on relapsed leukemic cells should be checked before donor lymphocyte infusion. (*Blood*. 2010;115(15):3158-3161)

Introduction

Human leukocyte antigen (HLA) molecules expressed on the cell surface are required in presenting antigens to T cells. The HLA class I antigens are vital in the recognition of tumor cells by tumor-specific cytotoxic T cells. The loss of HLA class I molecules on the cell surface membrane may lead to escape from T-cell immunosurveillance and the relapse of leukemia. Previously, loss of HLA class I haplotype has been described in solid tumors.¹⁻³ However, there are few reports concerning HLA-haplotype loss in leukemia.^{4,5}

We examined HLA class I expression in leukemic blasts from patients who relapsed after hematopoietic stem cell transplantation (HSCT) to analyze whether the loss of HLA on leukemic cells was related to the relapse after HLA-identical or haploidentical HSCT.

Methods

Patients and transplantation procedure

We identified 9 children with acute leukemia who relapsed after HSCT. Their leukemic samples were cryopreserved both at the time of the initial diagnosis and of relapse. The patients' characteristics are summarized in supplemental Table 1 (available on the *Blood* website; see the Supplemental Materials link at the top of the online article). Three patients received HSCT from an HLA-haploidentical family donor, and the other 6 patients received HSCT from an HLA-matched donor (4 siblings and 2 unrelated donors).

Written informed consent was given by the parents according to the protocol approved by the ethics committee of Nagoya University Graduate School of Medicine in accordance with the Declaration of Helsinki.

HLA class I expression on leukemic cells

Samples were collected at diagnosis and post-transplantation relapse. HLA expression of leukemic blasts and normal cells was analyzed by flow cytometry as previously reported.⁶ Anti-HLA A2-FITC (cloneBB7.2) and anti-HLA A24-FITC (clone17a10) monoclonal antibodies were purchased from Medical & Biological Laboratories; HLA-A11 (IgM), HLA-A30, HLA-31 (IgM), HLA-25, HLA-26 (IgM), HLA-Bw6 (IgG3), and HLA-Bw4 (IgG3) antibodies were purchased from One Lambda. For leukemic cell markers, CD13-PE (IgG1) were purchased from Immunotech and CD34-APC (IgG1) were purchased from BD Biosciences. Samples were analyzed with FACSCalibur cytometer and CellQuest software. The method of genomic HLA typing was previously reported.⁷

Isolation of DNA and single nucleotide polymorphism analysis

The CD13⁺/CD34⁺ leukemic blasts were sorted by flow cytometry from bone marrow cells at the time of diagnosis and of relapse. Genomic DNA was extracted from leukemic cells sorted by a fluorescence-activated cell sorter as well as from phytohemagglutinin-stimulated patient-derived T cells and subjected to single nucleotide polymorphism (SNP) array analysis using GeneChip NspI arrays (Affymetrix) according to the manufacturer's protocol. Allele-specific copy number was detected using Copy Number Analyzer for GeneChip software as previously described.⁸

Limiting dilution-based CTLp frequency assay

The frequencies of cytotoxic T-lymphocyte precursor (CTLp) specific for the recipient-mismatched HLA molecules were analyzed using a standard limiting dilution assay.⁹

Submitted November 15, 2009; accepted December 22, 2009. Prepublished online as *Blood* First Edition paper, February 1, 2010; DOI 10.1182/blood-2009-11-254284.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2010 by The American Society of Hematology




Figure 1. The loss of mismatched HLA expression on leukemic blasts caused by uniparental disomy on chromosome 6p impaired recognition and killing of donor's alloreactive cytotoxic T lymphocytes. (A) Leukemic blasts at the time of initial diagnosis and at the time of relapse after hematopoietic stem cell transplantation (HSCT) and donor lymphocyte infusion (DLI) were gated by CD34⁺ and CD13⁺, and then the surface expression of mismatched human leukocyte antigen (HLA) alleles was examined with anti-HLA-A2 antibodies. In 3 patients with acute myelogenous leukemia (AML) who experienced relapse after HLA-haploidentical HSCT, HLA-A2 expression was lost in patient 1 at relapse 15 months after HSCT and lost in patient 2 at second relapse 6 months after DLI. (B) Single nucleotide polymorphism (SNP) array analyses of sorted leukemic cells with the loss of an HLA allele revealed that the short arm of chromosome 6 shows copy number-neutral loss of heterozygosity or acquired uniparental disomy as detected by dissociated allele-specific copy number plots (red and blue lines at the bottom), resulting in the total loss of the mismatched HLA haplotype in both patient 1 and patient 2. The presence of acquired uniparental disomy is also indicated by normal total copy numbers with missing heterozygous SNPs (green bars) in the distal part of the short arm. (C) Recipient alloantigen-specific cytotoxic T-lymphocyte (CTL) clones were generated by a conventional cloning method from cytotoxicity-positive wells obtained in the limiting dilution assays using the donor CD8⁺ cells as responders. Donor CTL clones A1, A2, and A3 were specific for HLA-A*0206. Donor CTL clones B1 and B3 were specific for HLA-B*4001, all of which recognize mismatched HLA alleles between the donor and recipient. Those 5 representative CTL clones were tested for HLA specificity and recognition of leukemic blasts obtained at the time of the initial diagnosis and at the time of HLA loss relapse after DLI by a standard ⁵¹Cr-release assay at the effector/target ratio of 30:1. (D) Their interferon- γ production was also assessed against leukemic blasts collected at the time of diagnosis and at the time of HLA-loss relapse.

Cytotoxic assay of CTL clones against leukemic blasts and a mismatched HLA cDNA-transfected B-lymphoblastoid cell line

The remaining cells of several cytotoxicity-positive wells used for the CTLp assay for the donor were used to obtain allo-HLA-restricted CTLs. CTL clones were isolated by standard limiting dilution and expanded as previously described.^{10,11}

The HLA class I-deficient 721.221 B-lymphoblastoid cell line was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, and 1mM sodium pyruvate. Retroviral transduction was conducted as previously described.¹²

The cytotoxicity of CTL clones against target cells was analyzed by conventional chromium 51 (⁵¹Cr) release assay as previously reported.¹³

CTL clones (10⁴ cells/well) were mixed with the indicated stimulator cells (10⁴ cells/well) in 96-well, round-bottom polystyrene plates and spun at 1200g for 3 minutes before overnight incubation in 200 μ L of RPMI 1640 medium supplemented with 10% fetal bovine serum. On the next day, 50 μ L of supernatant was collected and interferon- γ

was measured by enzyme-linked immunosorbent assay with 3,3',5,5'-tetramethylbenzidine substrate (Sigma-Aldrich).

Results and discussion

Three children with high-risk acute myelogenous leukemia (AML) received haploidentical grafts from their parents but relapsed 8, 14, and 15 months after HSCT. Patient 2 received 3 courses of donor lymphocyte infusion (DLI) for relapsed leukemia after haploidentical HSCT. After the third unmanipulated DLI (10⁷ CD3⁺/kg), she experienced acute grade-III graft-versus-host disease and achieved complete remission. However, she experienced a second relapse 6 months later. To monitor residual disease in those patients, we used flow cytometric analysis with antibodies specific for the mismatched HLA alleles between the donor and patient. Surprisingly, we found total loss of

HLA-A2 expression on CD13⁺/CD34⁺ leukemic cells from bone marrow in 2 of 3 patients who underwent HLA-haploidentical HSCT, whereas microscopic analysis showed relapse (Figure 1A). To test whether HLA class I molecules could be up-regulated, samples were cultured for 48 hours in medium supplemented with tumor necrosis factor- α or interferon- γ and measured again; however, no restoration was observed (data not shown).

Next, to examine the potential loss of genes encoding the undetectable HLA alleles, we sorted CD13⁺/CD34⁺ leukemic blasts and performed DNA genotyping. We found that, in addition to the HLA-A locus, the HLA-B, -C, and -DR loci were not encoded; only the mismatched haplotype was lost in both patients (supplemental Table 2). We then questioned whether this phenomenon would also occur in HLA-matched HSCT settings using anti-HLA class I antibodies. We did not observe any loss of HLA class I expression in any of the patients at the time of relapse (supplemental Figure 1). These results suggest that loss of HLA class I haplotype at the time of posttransplantation relapse is uncommon in HLA-matched HSCT.

To elucidate the mechanism of the loss of the mismatched HLA haplotype, we performed an SNP array analysis of genomic DNA extracted from leukemic blasts at the time of diagnosis and of relapse. Genomic DNA from patient-derived T cells was used as a reference. Leukemic cells at the time of relapse showed copy number-neutral loss of heterozygosity or an acquired uniparental disomy (UPD) of the short arm of chromosome 6 encompassing the HLA locus, whereas no allelic imbalance was identified at the time of diagnosis (Figure 1B). Loss of one allele from one parent and duplication of the remaining allele from the other parent led to UPD.¹⁴

In patient 2, we examined whether the number of CTLp had changed during the posttransplantation course. Limiting dilution analysis with a split-well ⁵¹Cr-release assay was carried out to compare the CTLp frequencies specific for the mismatched antigens between the recipient and donor. Interestingly, the CTLp frequencies were recovered after DLI (Table 1). Restoration of CTLp after 3 DLIs could eradicate such leukemic cells, lasting for 6 months thereafter.

Next, we generated allo-HLA-restricted CTLs from CD8⁺ cells obtained at day 520 in patient 2 and tested with the 721.221 B-lymphoblastoid cell line transfected with 1 of 3 mismatched HLA alleles (Figure 1C-D).

Despite high transplantation-related mortality resulting from severe graft-versus-host disease and posttransplantation infections, haploidentical HSCT has been widely used with the expectation of a strong graft-versus-leukemia effect.¹⁵ However, our observation provides a possible limitation of this strategy. Indeed, 2 of 3 patients showed genomic loss of the recipient-specific HLA-haplotype, which led to escape from the graft-versus-leukemia effect and relapse of the disease.

Vago et al also reported a similar observation in 5 of 17 (29.4%) patients whose disease relapsed after haploidentical HSCT.¹⁶ Relapsed leukemic cells may possess genomic instability that elicits genetic diversity.¹⁷ Immunologic pressure by alloreaction to major HLA antigens may select leukemic variants of HLA class I loss, which results in the survival and proliferation of these variants.

In haploidentical HSCT, the importance of natural killer (NK)-cell alloreactivity is emphasized to achieve the graft-versus-leukemia effect.^{18,19} HLA loss on leukemic blasts may in turn enhance the NK-cell alloreactivity. Our 2 patients with HLA loss had a group 1 homozygous HLA-C locus that is a suppressive killer immunoglobulin-like receptor (KIR) for NK cells and a KIR-mismatched donor (supplemental Table 2). Because UPD does not

Table 1. The CTLp frequency reactive to the recipient alloantigen in the recipient after transplantation and the donor

Samples	Maximum CD8 ⁺ input*	No. of growing wells†	CTLp frequency ⁻¹ (95% confidence interval)
Donor	33 300	8	8.6×10^5 (1.49×10^6 - 5.0×10^5)
Day 100	35 500	0	UD
Day 180	17 700	0	UD
Day 300‡	86 000	0	UD
Day 520§	95 000	7	4.3×10^5 (7.2×10^5 - 2.5×10^5)

Purified CD8⁺ T cells from the peripheral blood mononuclear cells obtained after transplantation from patient 2 and her donor were cultured at 2- or 3-fold serial dilutions with 33 Gy-irradiated 3×10^4 leukemic blasts cryopreserved at the time of initial diagnosis in 96-well, round-bottom plates in advanced RPMI 1640 medium supplemented with 4% pooled human serum, interleukin-6 (IL-6), and IL-7 (10 ng/mL; both from R&D Systems). The IL-2 (50 U/mL) was added on day 7 with a half medium change. For each dilution, there were at least 12 replicates. On day 14 of culture, a split-well analysis was performed for recipient-specific cytotoxicity against ⁵¹Cr-radiolabeled recipient T-cell blasts, donor T-cell blasts, and leukemic blasts harvested at the time of initial diagnosis and at the time of relapse after DLI if indicated. The supernatants were measured in a γ counter after 4-hour incubation. The wells were considered to be positive for cytolytic activity if the total counts per minute released by effector cells was more than 3 SD above the control wells (mean counts per minute released by the target cells incubated with irradiated stimulator cells alone). The CTLp frequency was calculated using L-Calc software (StemCell Technologies). The CTLp frequencies reactive with recipient T-cell blasts in CD8⁺ T cells obtained around days 100, 180, and 300 (4 months before relapse) were undetectable, whereas the CTLp frequency obtained at day 520 (1 month after the third DLI or 2 weeks after remission confirmed by bone marrow aspirate) was close to the CTLp frequency in the donor CD8⁺ cells. Complete remission and more than 99% donor chimerism were confirmed on those days.

CTLp indicates CTL precursor; and UD, undetermined because no growing wells are present.

*Number of input CD8⁺ T cells seeded at the highest number per well.

†Number of wells out of 12 wells that received the highest CD8⁺ cells and showed detectable growth.

‡Corresponds to 4 months before relapse.

§Corresponds to 1 month after the third DLI or 2 weeks after complete remission was confirmed by bone marrow aspirate.

change the total copy number of the gene, donor NK cells should have been suppressed even after UPD occurred in these patients. Interestingly, the remaining patient who experienced relapse without HLA loss after HLA-haploidentical HSCT had a KIR-mismatched donor, so alloreactive NK cells were possibly enhanced to kill leukemic blasts with HLA loss.

Although one limitation of our study is an insufficient number of cases, our results combined with those in a recent report¹⁶ suggest that leukemic cells occasionally escape from immunosurveillance through the loss of the mismatched HLA haplotype by the mechanism of UPD after haploidentical HSCT. DLI for relapsed AML is less effective than that for chronic myelogenous leukemia after HLA-matched HSCT.²⁰ However, DLI is effective even for the relapse of AML after haploidentical HSCT.²¹ Evaluation of loss or down-regulation of HLA on relapsed leukemic blasts after HLA-haploidentical HSCT should be considered because DLI would probably be ineffective in patients whose leukemic cells lose HLA class I antigen.

Acknowledgments

This work was supported in part by the Ministry of Education, Culture, Science, Sports, and Technology, Japan (Grant for Scientific Research on Priority Areas; B01 no. 17016089); Grants for Research on the Human Genome, Tissue Engineering Food Biotechnology, and the Second and Third Team Comprehensive 10-year Strategy for Cancer Control (no. 26) from the Ministry of Health, Labor, and Welfare, Japan; Core Research for Evolutional Science and Technology of Japan

(Grant-in-Aid); the College Women's Association of Japan (scholarship award, I.B.V.); a grant from Foundation for Promotion of Cancer Research; and a grant from Morinaga Hoshikai and Grant-in-Aid for Scientific Research (c) No. 20591252.

Authorship

Contribution: I.B.V. performed experiments and wrote the manuscript; Y.T. designed the research, analyzed data, and wrote

the manuscript; Y.A., H.S., M.K., and S.O. performed experiments, analyzed data, and wrote the manuscript; S.K. supervised this work and wrote the manuscript; and all other authors were responsible for clinical work and critically reviewed the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Seiji Kojima, Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan; e-mail: kojimas@med.nagoya-u.ac.jp.

References

- Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. *Immunol Today*. 1997;18(2):89-95.
- Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. *Semin Cancer Biol*. 2002;12(1):3-13.
- Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Adv Immunol*. 2000;74:181-273.
- Wetzler M, Baer MR, Stewart SJ, et al. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. *Leukemia*. 2001;15(1):128-133.
- Masuda K, Hiraki A, Fujii N, et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts. *Cancer Sci*. 2007;98(1):102-108.
- Takahashi Y, McCoy JP Jr, Carvallo C, et al. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. *Blood*. 2004;103(4):1383-1390.
- Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program. *N Engl J Med*. 1998;339(17):1177-1185.
- Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. *Cancer Res*. 2005;65(14):6071-6079.
- Torikai H, Akatsuka Y, Miyazaki M, et al. A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. *J Immunol*. 2004;173(11):7046-7054.
- Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. *J Exp Med*. 2003;197(11):1489-1500.
- Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. *J Immunol Methods*. 1990;128(2):189-201.
- Kondo E, Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. *J Immunol*. 2002;169(4):2164-2171.
- Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. *J Clin Invest*. 2008;118(3):1099-1109.
- Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. *Trends Mol Med*. 2009;15(3):120-128.
- Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. *Biol Blood Marrow Transplant*. 2007;13(11):1249-1267.
- Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. *N Engl J Med*. 2009;361(5):478-488.
- Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. *Nat Immunol*. 2002;3(11):999-1005.
- Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science*. 2002;295(5562):2097-2100.
- Velardi A, Ruggeri L, Mancusi A, et al. Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. *Semin Immunopathol*. 2008;30(4):489-503.
- Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. *Blood*. 2008;112(12):4371-4383.
- Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. *Haematologica*. 2007;92(3):414-417.

HapMap scanning of novel human minor histocompatibility antigens

*Michi Kamei,^{1,2} *Yasuhiro Nannya,^{3,5} Hiroki Torikai,¹ Takakazu Kawase,^{1,6} Kenjiro Taura,⁷ Yoshihiro Inamoto,⁸ Taro Takahashi,⁸ Makoto Yazaki,⁹ Satoko Morishima,¹ Kunio Tsujimura,¹⁰ Koichi Miyamura,^{5,8} Tetsuya Ito,² Hajime Togari,² Stanley R. Riddell,¹¹ Yoshihisa Kodera,^{5,8} Yasuo Morishima,^{5,12} Toshitada Takahashi,¹³ Kiyotaka Kuzushima,¹ †Seishi Ogawa,^{4,5} and †Yoshiki Akatsuka^{1,5}

¹Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan; ²Department of Pediatrics and Neonatology, Nagoya City University, Graduate School of Medical Science, Nagoya, Japan; ³Department of Hematology/Oncology and ⁴The 21st Century Center of Excellence (COE) Program, Graduate School of Medicine, University of Tokyo, Tokyo, Japan; ⁵Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, Japan; ⁶Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan; ⁷Department of Information and Communication Engineering, Graduate School of Information Science, University of Tokyo, Tokyo, Japan; ⁸Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; ⁹Department of Pediatrics, Higashi Municipal Hospital of Nagoya, Nagoya, Japan; ¹⁰Department of Infectious Diseases, Hamamatsu University School of Medicine, Hamamatsu, Japan; ¹¹Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ¹²Department of Hematology and Cell Therapy, Aichi Cancer Center Central Hospital, Nagoya, Japan; and ¹³Aichi Comprehensive Health Science Center, Aichi Health Promotion Foundation, Chita-gun, Japan

Minor histocompatibility antigens (mHags) are molecular targets of alloimmunity associated with hematopoietic stem cell transplantation (HSCT) and involved in graft-versus-host disease, but they also have beneficial antitumor activity. mHags are typically defined by host SNPs that are not shared by the donor and are immunologically recognized by cytotoxic T cells isolated from post-HSCT patients. However, the number of molecularly identified mHags is still too small to allow prospective studies of their clinical

importance in transplantation medicine, mostly due to the lack of an efficient method for isolation. Here we show that when combined with conventional immunologic assays, the large data set from the International HapMap Project can be directly used for genetic mapping of novel mHags. Based on the immunologically determined mHag status in HapMap panels, a target mHag locus can be uniquely mapped through whole genome association scanning taking advantage of the unprecedented resolution and power ob-

tained with more than 3 000 000 markers. The feasibility of our approach could be supported by extensive simulations and further confirmed by actually isolating 2 novel mHags as well as 1 previously identified example. The HapMap data set represents an invaluable resource for investigating human variation, with obvious applications in genetic mapping of clinically relevant human traits. (*Blood*. 2009;113:5041-5048)

Introduction

The antitumor activity of allogeneic hematopoietic stem cell transplantation (HSCT), which is a curative treatment for many patients with hematologic malignancies, is mediated in part by immune responses that are elicited as a consequence of incompatibility in genetic polymorphisms between the donor and the recipient.^{1,2} Analysis of patients treated for posttransplantation relapse with donor lymphocytes has shown tumor regression to be correlated with expansion of cytotoxic T lymphocytes (CTLs) specific for hematopoiesis-restricted minor histocompatibility antigens (mHags).^{3,4} mHags are peptides, presented by major histocompatibility complex (MHC) molecules, derived from intracellular proteins that differ between donor and recipient due mostly to single nucleotide polymorphisms (SNPs) or copy number variations (CNVs).^{1,2,5} Identification and characterization of mHags that are specifically expressed in hematopoietic but not in other normal tissues could contribute to graft-versus-leukemia/lymphoma (GVL) effects, while minimizing unfavorable graft-versus-host disease, one of the most serious complications of allo-HSCT.^{1,2} Unfortu-

nately, however, efforts to prospectively target mHags to invoke T cell-mediated selective GVL effects have been hampered by the scarcity of eligible mHags, largely due to the lack of efficient methods for mapping the relevant genetic loci. Several methods have been developed to identify mHags, including peptide elution from MHC,^{6,7} cDNA expression cloning,^{8,9} and linkage analysis.^{3,10} We have recently reported a novel genetic method that combines whole genome association scanning with conventional chromium release cytotoxicity assays (CRAs). With this approach the genetic loci of the mHag gene recognized by a given CTL clone can be precisely identified using SNP array analysis of pooled DNA generated from immortalized lymphoblastoid cell lines (LCLs) that are immunophenotyped into mHag⁺ and mHag⁻ groups by CRA.¹¹ The mapping resolution has now been improved from several Mb for conventional linkage analysis to an average haplotype block size of less than 100 kb,¹² usually containing a handful of candidate genes. Nevertheless, it still requires laborious DNA pooling and scanning of SNP arrays with professional expertise for individual

Submitted July 29, 2008; accepted August 27, 2008. Prepublished online as *Blood* First Edition paper, September 22, 2008; DOI 10.1182/blood-2008-07-171678.

*M.K. and Y.N. are first coauthors and contributed equally to this work.

†S.O. and Y.A. are senior coauthors.

An Inside *Blood* analysis of this article appears at the front of this issue.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2009 by The American Society of Hematology

CTLs.¹¹ To circumvent these drawbacks, we have sought to take advantage of publicly available HapMap resources. Here, we describe a powerful approach for rapidly identifying mHag loci using a large genotyping data set and LCLs from the International HapMap Project for genome-wide association analysis.¹³⁻¹⁵

Methods

Cell lines and CTL clones

The HapMap LCL samples were purchased from the Coriell Institute (Camden, NJ). All LCLs were maintained in RPMI1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 1 mM sodium pyruvate. Because the recognition of a mHag requires presentation on a particular type of HLA molecule, the LCLs were stably transduced with a retroviral vector encoding the restriction HLA cDNA for a given CTL clone when necessary.¹⁶

CTL lines were generated from recipient peripheral blood mononuclear cells obtained after transplantation by stimulation with those harvested before HSCT after irradiation (33 Gy), and thereafter stimulated weekly in RPMI 1640 supplemented with 10% pooled human serum and 2 mM L-glutamine. Recombinant human interleukin-2 was added on days 1 and 5 after the second and third stimulations. CTL clones were isolated by standard limiting dilution and expanded as previously described.^{10,17} HLA restriction was determined by conventional CRAs against a panel of LCLs sharing HLA alleles with the CTLs. All clinical samples were collected based on a protocol approved by the Institutional Review Board Committee at Aichi Cancer Center and the University of Tokyo and after written informed consent was obtained in accordance with the Declaration of Helsinki.

Immunophenotyping of HapMap LCLs and high-density genome-wide scanning of mHag loci

Case (mHag⁺) - control (mHag⁻) LCL panels were generated by screening corresponding restriction HLA-transduced CHB and JPT HapMap LCL panels with each CTL clone using CRAs. Briefly, target cells were labeled with 0.1 mCi of ⁵¹Cr for 2 hours, and 10³ target cells per well were mixed with CTL at a predetermined E/T ratio in a standard 4-hour CRA. All assays were performed at least in duplicate. The percent specific lysis was calculated by ((Experimental cpm - Spontaneous cpm) / (Maximum cpm - Spontaneous cpm)) × 100. After normalization by dividing their percent specific lysis values by that of positive control LCL (typically recipient-derived LCL corresponding to individual CTL clones), the mHag status of each HapMap LCL was defined as positive, negative, or undetermined.

To identify mHag loci, we performed association tests for all the Phase II HapMap SNPs, by calculating χ^2 test statistics based on 2 × 2 contingency tables with regard to the mHag status as measured by CRA and the HapMap genotypes (presence or absence of a particular allele) at each locus. χ^2 were calculated for the 2 possible mHag alleles at each locus and the larger value was adopted for each SNP. While different test statistics may be used showing different performance, the χ^2 statistic is most convenient for the purpose of power estimation as described below. The maximum value of the χ^2 statistics was evaluated against the thresholds empirically calculated from 100 000 random permutations within a given LCL set. The program was written in C++ and will run on a unix clone. It will be freely distributed on request. Computation of the statistics was performed within several seconds on a Macintosh equipped with 2 × quadcore 3.2 GHz Zeon processors (Apple, Cupertino, CA), although 100 000 permutations took several hours on average.

Evaluation of the power of association tests using HapMap samples

The genotyping data of the Phase II HapMap¹⁴ were obtained from the International HapMap Project website (http://www.hapmap.org/genotypes/latest_ncbi_build35), among which we used the nonredundant data sets

(excluding SNPs on the Y chromosome) from 60 CEU (Utah residents with ancestry from northern and western Europe) parents, 60 YRI (Yoruba in Ibadan, Nigeria) parents, and the combined set of 45 JPT (Japanese in Tokyo, Japan) and 45 CHB (Han Chinese in Beijing, China) unrelated people. They contained 3 901 416 (2 624 947 polymorphic), 3 843 537 (295 293 polymorphic), and 3 933 720 (2 516 310 polymorphic) SNPs for CEU, YRI, and JPT + CHB, respectively.

To evaluate the power, we first assumed that the Phase II HapMap SNP set contains the target SNP of the relevant mHag or its complete proxies, and that the immunologic assays can completely discriminate i mHag⁺ and j mHag⁻ HapMap LCLs. Under this ideal condition, the test statistic, or χ^2 , for these SNPs takes a definite value, $f(i,j) = i+j$, which was compared with the maximum χ^2 value, or its distribution, under the null hypothesis, that is, no SNPs within the Phase II HapMap set should be associated with the mHag locus. Unfortunately, the latter distribution cannot be calculated in an explicit analytical form but needs to be empirically determined based on HapMap data, because Phase II HapMap SNPs are mutually interdependent due to extensive linkage disequilibrium within human populations. For this purpose, we simulated 10 000 case-control panels by randomly choosing i mHag⁺ and j mHag⁻ HapMap LCLs for various combinations of (i,j) and calculated the maximum χ^2 values (χ^2_{\max}) for each panel to identify those (i,j) combinations, in which $f(i,j)$ exceeds the upper 1 percentile point of the simulated 10 000 maximum values, $g(i,j)^P = .01$.

When proxies are not complete (ie, $r^2 < 1$), the expected values will be decayed by the factor of r^2 , and further reduced due to the probabilities of false positive (f_p) and negative (f_n) assays, and expressed as $\hat{f}(i,j) = (i+j) \times r^2$ through an apparent r^2 (\hat{r}^2) as provided in formula 1.¹ Under given probabilities of assay errors and maximum LD strength between markers and the mHag allele, we can expect to identify target mHag loci for those (i,j) sets that satisfy $\hat{f}(i,j) > g(i,j)^P = .01$.

Empirical estimation of distributions of r^2

The maximum r^2 value (r^2_{\max}) between a given mHag allele and one or more Phase II HapMap SNPs was estimated based on the observed HapMap data set. Each Phase II HapMap SNP was assumed to represent a target mHag allele, and the (r^2_{\max}) was calculated, taking into account all the Phase II HapMap SNPs less than 500 kb apart from the target SNP.

Confirmatory genotyping

Genotyping was carried out either by TaqMan MGB technology (Applied Biosystems, Foster City, CA) with primers and probes for HA-1 mHag according to the manufacturer's protocol using an ABI 7900HT with the aid of SDS version 2.2 software (Applied Biosystems) or by direct sequencing of amplified cDNA for the *SLCIA5* gene. cDNA was reverse transcribed from total RNA extracted from LCLs, and polymerase chain reaction (PCR) was conducted with cDNA with the corresponding primers. Amplified DNA samples were sequenced using BigDye Terminator version 3.1 (Applied Biosystems). The presence or absence (deletion) of the *UGT2B17* gene was confirmed by genomic PCR with 2 primer sets for exons 1 and 6 as described previously¹⁸ using DNA isolated from LCLs of interest.

Epitope mapping

A series of deletion mutant cDNAs were designed and cloned into pcDNA3.1/V5-His TOPO plasmid (Invitrogen, Carlsbad, CA). Thereafter, 293T cells that had been transduced with restricting HLA class I cDNA for individual CTL clones were transfected with each of the deletion mutants and cocultured with the CTL clone overnight to induce interferon (IFN)- γ release, which was then evaluated by enzyme-linked immunosorbent assay (ELISA) as previously described.⁹

For *SLCIA5*, expression plasmids encoding full-length cDNA and the exon 1 of recipient and donor origin were first constructed because only the SNP in the exon 1 was found to be concordant with susceptibility to CTL-3B6. Next, amino (N)- and (carboxyl) C-terminus-truncated mini-genes encoding polypeptides around the polymorphic amino acid defined by the SNP were amplified by PCR from *SLCIA5* exon 1 cDNA as template and cloned into the above plasmid. The constructs all encoded a Kozak




Figure 1. Numbers of positive and negative LCLs required for successful mHag mapping. The target locus was assumed to be uniquely identified, if the expected χ^2 value for the target SNP ($\hat{K}(i,j)$, see Document S1) exceeded the upper 1 percentile point of the maximum χ^2 values in 10 000 simulated case-control panels ($g(i,j)^{P=0.1}$). Combinations of the numbers of mHag⁺ (vertical coordinates) and mHag⁻ (horizontal coordinates) samples satisfying the above condition are shown in color gradients corresponding to different max r^2 values between the target SNP and one or more nearby Phase II HapMap SNPs (r^2_{\max}), ranging from 0.4 to 1.0. Calculations were made for 3 HapMap population panels, CHB + JPT (top), YRI (middle), and CEU (bottom) and for different false positive and negative rates, $f_P = f_N = 0$ (left), $f_P = 0.1, f_N = 0$ (middle), and $f_P = 0.1, f_N = 0.05$ (right), considering the very low false negative assays for CRAs.

sequence and initiator methionine (CCACC-ATG) and for C-terminus deletions a stop codon (TAG).

For *UGT2B17*, a series of C-terminus deletion mutants with approximately 200 bp spacing was first constructed as above. For further mapping, N-terminus deletion mutants were added to the region that was deduced to be potentially encoding the CTL-1B2 epitope. For prediction of a CTL epitope, the HLA Peptide Binding Predictions algorithm on the Bioinformatics & Molecular Analysis Section (BIMAS) website (http://www.bimas.cit.nih.gov/molbio/hla_bind/)¹⁹ was used because HLA-A*0206 has a similar binding motif to that of A*0201.

Epitope reconstitution assay

The candidate mHag epitopes and allelic counterpart peptides (in case of SLC1A5) were synthesized by standard Fmoc chemistry. ⁵¹Cr-labeled mHag⁻ donor LCL were incubated with graded concentrations of the peptides and then used as targets in standard CRAs.

Results and discussion

Statistical approach and estimation of potential overfitting

We reasoned that the mHag locus recognized by a given CTL clone could be defined by grouping LCLs from a HapMap panel into

mHag⁺ and mHag⁻ subpanels according to their susceptibility to lysis by the CTL clone and then performing an association scan using the highly qualified HapMap data set containing more than 3 000 000 SNP markers. The relevant genetic trait here is expected to show near-complete penetrance, and the major concern with this approach arises from the risk of overfitting observed phenotypes to one or more incidental SNPs with this large number of HapMap SNPs under the relatively limited size of freedom due to small numbers of independent HapMap samples (90 for JPT + CHB and 60 for CEU and YRI, when not including their offspring).¹³

To address this problem, we first estimated the maximum sizes of the test statistics (here, χ^2 values) under the null hypothesis (ie, no associated SNPs within the HapMap set) by simulating 10 000 case-control HapMap panels under different experimental conditions, and compared them with the expected size of test statistic values from the marker SNPs associated with the target SNP, assuming different linkage disequilibrium (LD), or r^2 values in between. As shown in Figure 1, the possibility of overfitting became progressively reduced as the number of LCLs increased, which would allow for identification of the target locus in a broad range of r^2 values, except for those mHags having very low minor allele frequencies (MAF) below




Figure 2. Genome-wide scanning to identify chromosome location of mHag. χ^2 values were plotted against positions on each chromosome for each of 3 mHags recognized by CTL-4B1 (A), CTL-3B6 (B), and CTL-1B2 (C). Chromosomes are displayed in alternating colors. Threshold χ^2 values corresponding to the genome-wide $P = 10^{-3}$ (dark blue) and 10^{-2} (light blue), as empirically determined from 100 000 random permutations, are indicated by broken lines, while the theoretically possible maximum values are shown with red broken lines. The highest χ^2 value in each experiment is indicated by a red arrow.

approximately 0.05. According to our estimation using the Phase II HapMap data (see “Methods”), the majority (> 90%) of common target SNPs ($MAF > \sim 0.05$) could be captured by one or more HapMap SNPs with more than 0.8 of r^2 (Figure S1, available on the *Blood* website; see the Supplemental Materials link at the top of the online article), ensuring a high probability of detecting an association (Figure 1 left panels). The simulation of pseudo-Phase II sets generated from the ENCODE regions provided a similar estimation.¹³ False positive and negative immunophenotyping results could also complicate the detection, reducing the expected test statistics through the “apparent” r^2 values (\hat{r}^2), as defined by

$$(1) \quad \hat{r}^2 = r^2 \times \frac{(1 - f_P - f_N)^2}{(1 - f_P + f_N q)(1 - f_N + f_P q)}$$

where f_P , f_N , and q represent false typing probabilities with positive and negative LCL panels, and the ratio of the positive to the negative LCL number, respectively. However, the high precision of cytotoxicity assays ($f_P \sim < 0.1$, $f_N \sim 0$) limits this drawback from the second term to within acceptable levels and allows for sensitive mHag locus mapping with practical sample sizes (Figure 1 middle and right panels), suggesting the robustness of our novel approach.

Evaluation of the detection power for known mHags

Based on these considerations, we then assessed whether this approach could be used to correctly pinpoint known mHag loci (Table S1). Because the relevant mHag alleles are common SNPs and directly genotyped in the Phase II HapMap set, or if not, located within a well-defined LD block recognized in this set (Figure S2), their loci would be expected to be uniquely determined with an acceptable number of samples, as predicted from Figure 1. To test this experimentally, we first mapped the locus for HA-1^H mHag⁷ by evaluating recognition of the HLA-A*0206-transduced HapMap cell panel with HLA-A*0206-restricted CTL-4B1.²⁰ After screening 58 well-growing LCLs from the JPT + CHB panel with CRAs using CTL-4B1 (Figure S3A; Tables S2,S3), we obtained 37 mHag⁺ and 21 mHag⁻ LCLs, which were tested for association at 3 933 720 SNP loci. The SNP (rs1801284) encoding the mHag is located within a HapMap LD block on chromosome 19q13.3, but is not directly genotyped within this data set. The genome-wide scan clearly indicated a unique association with the HA-1^H locus within the *HMHA1* gene, showing a peak χ^2 statistic of 52.8 (not reached in 100 000 permutations) at rs10421359 (Figures 2A,3A; Tables S2,S3).




Figure 3. Regions of mHag loci identified by HapMap scanning. LD structures around the SNPs showing peak statistical values (in JPT + CHB) are presented for each mHag locus identified with (A) CTL-4B1, (B) CTL-3B6, and (C) CTL-1B2. Regional χ^2 plots are also provided on the top of each panel. LD plots in pairwise D's with recombination rates along the segment were drawn with HaploView software version 4.0 (<http://www.broad.mit.edu/mpg/haploview/>). The size and location of each LD block containing a mHag locus are indicated within the panels. Significant SNPs (blue letters), as well as other representative SNPs, are shown in relation to known genes. The positions of the SNPs showing the highest statistic values (red letters) are indicated by red arrowheads.

Identification of novel mHags

We next applied this method to mapping novel mHags recognized by CTL clone 3B6, which is HLA-B*4002-restricted; and CTL clone 1B2, which is HLA-A*0206-restricted. Both clones had been isolated from peripheral blood samples of post-HSCT different patients. In preliminary CRAs with the JPT + CHB panel, allele frequencies of target mHags for CTL-3B6 and CTL-1B2 in this panel were estimated as approximately 25% and approximately 45%, respectively (data not shown). After screening

72 JPT + CHB LCLs with CTL-3B6, 36 mHag⁺ and 14 mHag⁻ LCLs were obtained, leaving 22 LCLs undetermined based on empirically determined thresholds (> 51% for mHag + LCLs and < 11% for mHag-LCLs; Figure S3B, Tables S2,S4). As shown in Figure 2B, the χ^2 statistics calculated from the immunophenotyping data produced discrete peaks in the LCL sets. The peak in chromosome 19q13.3 for the CTL-3B6 set showed the theoretically maximum χ^2 value of 50 (not reached in 100 000 permutations) at rs3027952, which was mapped within a small LD block of

because endogenous expression of a minigene encoding AEPTANG-LAL was not recognized by CTL-3B1 (Figure 4B). Unfortunately, although the peak statistic value showed the theoretically maximum value for this data set, it did not conform to the relevant SNP for this mHag (rs3027956) due to high genotyping errors of the HapMap data at this particular SNP. However, the result of our resequencing showed complete concordance with the presence of the rs3027956 SNP and recognition in the cytotoxicity assay (Table S4).

Similarly, 13 mHag⁺ and 32 mHag⁻ LCLs were identified from the screening of 45 JPT LCLs from the same panel using CTL-1B2 (Figure S3C; Tables S2,S5). The χ^2 statistics calculated from the immunophenotyping data produced bimodal discrete peaks with this LCL set. The target locus for the mHag recognized by CTL-1B2 was identified at a peak (max $\chi^2 = 44$, not reached in 100 000 permutations) within a 598-kb block on chromosome 4q13.1, coinciding with the locus for a previously reported mHag, *UGT2B17*¹⁸ (Figures 2C, 3C). In fact, our epitope mapping using *UGT2B17* cDNA deletion mutants (Figure 4C), prediction of candidate epitopes by HLA-binding algorithms¹⁹ (Figure 4D) and epitope reconstitution assays (Figure 4E), successfully identified a novel nonameric peptide, CVATMIFMI. Of particular note, this mHag was not defined by a SNP but by a CNV (ie, a null allele¹⁸) that is in complete LD with the SNPs showing the maximum χ^2 value (Table S5). Transplanted T cells from donors lacking both *UGT2B17* alleles are sensitized in recipients possessing at least 1 copy of this gene.¹⁸ Although LD between SNPs and CNVs has been reported to be less prominent,²¹ this is an example where a CNV trait could be captured by a SNP-based genome-wide association study.

The recent generation of the HapMap has had a profound impact on human genetics.^{13,15} In the field of medical genetics, the HapMap is a central resource for the development of theories and methods that have made well-powered, genome-wide association studies of common human diseases a reality.²²⁻²⁸ The HapMap samples provide not only an invaluable reference for genetic variations within human populations, but highly qualified genotypes that enable gene-wide scanning. Here, we have demonstrated how effectively HapMap resources can be used for genetic mapping of clinically relevant human traits. No imputations and tagging strategies are required^{25,28} and the potential loss of statistical power due to very limited sample sizes is circumvented by accurate immunologic detection of the traits.

Using publicly available HapMap resources, high-throughput identification of mHag genes is possible without highly specialized equipment or expensive microarrays. Except for clinically irrelevant mHags with very low allele frequencies (eg, MAF < 5%), the target of a given CTL can be sensitively mapped within a mean LD block size, typically containing just a few candidate genes. The methodology described here will facilitate construction of a large panel of human mHags including those presented by MHC class II molecules, and promote our understanding of human allo-

immunity and development of targeted allo-immune therapies for hematologic malignancies.^{1,2} The HapMap scan approach may be useful for exploring other genetic traits or molecular targets (eg, differential responses to some stress or drugs), if they can be discriminated accurately through appropriate biologic assays. In this context, the recent report that we may reprogram the fate of terminally differentiated human cells²⁹ is encouraging, indicating possible exploration of genotypes that are relevant to cell types other than immortalized B cells.

Acknowledgments

We thank Drs P. Martin and W. Ho for critically reading the manuscript; and Ms Keiko Nishida, Dr Ayako Demachi-Okamura, Dr Yukiko Watanabe, Ms Hiromi Tamaki, and the staff members of the transplant centers for their generous cooperation and technical expertise.

This study was supported in part by a grant for Scientific Research on Priority Areas (B01; no.17016089) from the Ministry of Education, Culture, Science, Sports, and Technology, Japan; grants for Research on the Human Genome, Tissue Engineering Food Biotechnology and the Second and Third Team Comprehensive 10-year Strategy for Cancer Control (no. 26) from the Ministry of Health, Labor, and Welfare, Japan; and a grant-in-aid from Core Research for Evolutional Science and Technology (CREST) of Japan.

Authorship

Contribution: M.K. performed most of immunologic experiments and analyzed data and wrote the manuscript; Y.N. performed the majority of genetic analyses and analyzed the data; H.T., T.K., M.Y., S.M. and K.Tsujimura performed research; K.Taura contributed to the computational simulation; Y.I., Taro T., K.M., Y.K. and Y.M. collected clinical data and specimens; T.I., H.T., S.R.R., Toshitada T. and K.K. contributed to data analysis and interpretation, and writing of the article; and Y.A. and S.O. supervised the entire project, designed and coordinated most of the experiments in this study, and contributed to manuscript preparation.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Seishi Ogawa, MD, PhD, Department of Hematology and Oncology, Department of Regeneration Medicine for Hematopoiesis, The 21st Century COE Program, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; e-mail: sogawa-tky@umin.ac.jp; or Yoshiki Akatsuka, MD, PhD, Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan; e-mail: yakatsuk@aichi-cc.jp.

References

- Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. *Nat Rev Cancer*. 2004;4:371-380.
- Spierings E, Goulmy E. Expanding the immunotherapeutic potential of minor histocompatibility antigens. *J Clin Invest*. 2005;115:3397-3400.
- de Rijke B, van Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. *J Clin Invest*. 2005;115:3506-3516.
- Marijt WA, Heemskerck MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. *Proc Natl Acad Sci U S A*. 2003;100:2742-2747.
- Spierings E, Hendriks M, Absi L, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. *PLoS Genet*. 2007;3:e103.
- Brickner AG, Warren EH, Caldwell JA, et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. *J Exp Med*. 2001;193:195-206.
- den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. *Science*. 1998;279:1054-1057.